Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 3, 2007, Pages

  Meier, Juris J ^a   Holst, Jens J ^b   Schmidt, Wolfgang E ^a   Nauck, Michael A ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Homeostasis model assessment; Microparticle enzyme immunoassay

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE INTAKE; HUMAN; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIVER CLEARANCE; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN; LIVER; MALE; METABOLIC CLEARANCE RATE; SIGNAL TRANSDUCTION;

EID: 34548389205     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00289.2007     Document Type: Article

References (45)

1. Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 48: 2140-2146, 2005.
2. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 281: E242-E247, 2001.
3. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996.
4. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
5. Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85: 3575-3581, 2000.
6. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Host JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
8. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 56: 1294-1300, 1983.
9. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158, 2003.
10. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a doseresponse study. Am J Physiol Endocrinol Metab 244: E517-E527, 1983.
11. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
12. Groop PH, Groop L, Totterman KJ, Fyhrquist F. Relationship between changes in GIP concentrations and changes in insulin and C-peptide concentrations after guar gum therapy. Scand J Clin Lab invest 46: 505-510, 1986.
13. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS. The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 115: 1011-1018, 1984.
14. Humphriss DB, Stewart MW, Berrish TS, Barriocanal LA, Trajano LR, Ashworth LA, Brown MD, Miller M, Avery PJ, Alberti KG, Walker M. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia 40: 1185-1190, 1997.
15. Kindmark H, Pigon J, Efendic S. Glucose-dependent insulinotropic hormone potentiates the hyopglycaemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. J Clin Endocrinol Metab 86: 2015-2019, 2001.
16. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52: 380-386, 2003.
17. Knutson VP. Cellular trafficking and processing of the insulin receptor. FASEB J 5: 2130-2138, 1991.
18. Madsbad S, Kehlet H, Hilsted J, Tronier B. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 32: 436-438, 1983.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
20. Meier JJ, Gallwitz BNS, Holst JJ, Deacon CF, Schmidt WE, Nauck MA. The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric Inhibitory polypeptide (GIP). Regul Pept 113: 95-100, 2003.
21. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725, 2003.
22. Meier JJ, Gethmann A, Goetze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 (GLP-1) abolishes the postprandial rise in triglyceride concentrations and lowers free fatty acid levels in humans. Diabetologia 49: 452-458, 2006.
23. Meier JJ, Hücking K, Holst JJ, Deacon C, Schmiegel W, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50: 2497-2504, 2001.
24. Meier JJ, Nauck MA. The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5: 402-410, 2004.
25. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in patients with chronic renal insufficiency and healthy controls. Diabetes 53: 654-662, 2004.
26. Meier JJ, Nauck MA, Siepmann N, Greulich M, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B. Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 52: 1579-1585, 2003.
27. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54: 1649-1656, 2005.
28. Nauck MA, El-Ouaghlidi A, Gabrys B, Hucking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 122: 209-217, 2004.
29. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
30. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
31. Pimenta WP, Santos ML, Cruz NS, Aragon FF, Padovani CR, Gerich JE. Insulin secretion, insulin sensitivity, and hepatic insulin extraction in first-degree relatives of type 2 diabetic patients. Braz J Med Biol Res 36: 301-308, 2003.
32. Polonsky K, Jaspan J, Emmanouel D, Holmes K, Moossa AR. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol (Copenh) 102: 420-427, 1983.
33. Polonsky K, Jaspan J, Pugh W, Cohen D, Schneider M, Schwartz T, Moossa AR, Tager H, Rubenstein AH. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction J Clin Invest 72: 1114-1123, 1983.
34. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33: 486-494, 1984.
35. Rubenstein AH, Clark JL, Melani F, Steiner D. Secretion of proinsulin and C-peptide by pancreatic beta-cells and its circulation in blood. Nature 224: 697-699, 1969.
36. Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 53: 2359-2365, 2004.
37. Sacca L, Orofino G, Petrone A, Vigorito C. Direct assessment of splanchnic uptake and metabolic effects of human and porcine insulin. J Clin Endocrinol Metab 59: 191-196, 1984.
38. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, Jensen MD, Rizza RA. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 51: 301-310, 2002.
39. Shapiro ET, Tillil H, Miller MA, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS. Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes 36: 1365-1371, 1987.
40. Shuster LT, Go VLW, Rizza RA, O'Brien PC, Service FJ. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 37: 200-203, 1988.
41. Tillil H, Shapiro ET, Miller A, Karrison T, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol Endocrinol Metab 254: E349-E357, 1988.
42. Tillil H, Shapiro ET, Rubenstein AH, Galloway JA, Polonsky KS. Reduction of insulin clearance during hyperglycemic clamp. Dose-response study in normal humans. Diabetes 37: 1351-1357, 1988.
43. Usdin TB, Mesey É, Button DC, Brownstein MJ, Booner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor familiy, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861-2870, 1993.
44. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45: 1111-1119, 2002.
45. Waldhausl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 17: 221-227, 1979.